Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen

Proskurina, Anastasia S.; Gvozdeva, Tatiana S.; Potter, Ekaterina A.; Dolgova, Evgenia V.; Orishchenko, Konstantin E.; Nikolin, Valeriy P.; Popova, Nelly A.; Sidorov, Sergey V.; Chernykh, Elena R.; Ostanin, Alexandr A.; Leplina, Olga Y.; Dvornichenko, Victoria V.; Ponomarenko, Dmitriy M.; Soldatova, Galina S.; Varaksin, Nikolay A.; Ryabicheva, Tatiana G.; Uchakin, Peter N.; Rogachev, Vladimir A.; Shurdov, Mikhail A.; Bogachev, Sergey S.

doi:10.1186/s12885-016-2711-5

Table 1 Patient data during the clinical trial of Panagen

From: Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen

Patient number	Breast cancer stage		1 year	1.5 years	2 years	3–4 years	5 years
FAC chemotherapy + Placebo
01–03	T2N1M0	IIB	remission	remission	remission	remission	remission
01–08	T2N0M0	IIA	remission	remission	remission	remission	remission
01–12	T4N3M1	IV	remission	remission	disease progression	deceased	–
01–16	T4N2M0	IIIB	remission	remission	deceased (cause of death is not cancer)	-	-
01–23	T4N0M0	IIIB	remission	remission	disease progression	no data	no data
02–07	T4N2M0	IIIB	deceased	-	-	-	-
02–12^a	T2N2M0	IIIA	remission	remission	no data	no data	no data
02–13	T4N3M0/1	IV	therapy continues	disease progression, lung metastases	deceased	-	-
02–17	T2N1M0	IIB	remission	remission	remission	remission	remission
AC chemotherapy + Placebo
02–23^a	T2N1M0/1	IV	disease progression, lymph node metastases before the study + bone metastases	deceased	-	-	-
02–32	T4NxM0	IIIB	remission	remission	remission	remission	no data
02–34	T4N2M0	IIIB	disease progression, metastases to bones, lungs, and soft tissues of the chest wall	no data	no data	no data	no data
02–35^a	T4NxM0	IIIB	remission	no data	no data	deceased	-
02–37^a	T4N0M0	IIIB	disease progression, brain, lungs, liver and bone metastases	deceased	-	-	-
02–38	T2N2M0	IIIA	no data	deceased	-	-	-
02–41	T1N1M0	IIA	remission	remission	remission	remission	no data
FAC chemotherapy + Panagen
01–01	T1N2M0	IIIA	remission	remission	remission	disease progression	no data
01–02	T1N2M0	IIIA	remission	remission	remission	disease progression	no data
01–04	T4N2M1	IV	remission	remission	remission	deceased	-
01–05	T2N1M0	IIB	remission	deceased	-	-	-
01–06	T4N1M0	IIIB	remission	remission	remission	remission	remission
01–07	T3N0M0	IIB	remission	remission	remission	remission	remission
01–09	T2N2M0	IIIA	remission	remission	remission	no data	no data
01–10	T4N3M0	IIIC	remission	remission	remission	remission	no data
01–11	T2N1M0	IIB	remission	remission	remission	remission	no data
01–13	T4N3M0	IIIC	remission	remission	remission	remission	remission
01–14	T4N2M0	IIIB	remission	remission	remission	disease progression	deceased
01–15	T2N2M0	IIIA	remission	remission	remission	remission	remission
01–17	T2N1M0	IIB	remission	remission	remission	no data	no data
01–18	T4N1M0	IIIB	disease progression	no data	no data	no data	alive
01–19	T4N1M0	IIIB	remission	remission	remission	deceased	–
01–20	T2N0M0	IIA	remission	remission	remission	remission	remission
01–21	T4N3M0	IIIC	disease progression	no data	no data	alive	alive
01–22	T4N1M1	IV	remission	remission	remission	disease progression	deceased
02–01	T4NxM0	IIIB	no data	no data	no data	disease progression, tumor disintegration, multiple metastases in lungs	deceased
02–02	T2N0M0	IIA	remission	remission	remission	no data	no data
02–03	T1N1M0	IIA	remission	remission	remission	disease progression, Th11 metastases	no data
02–04	T3N2M1	IV	deceased	-	-	-	-
02–05	T4N1M0	IIIB	remission	remission	remission	remission	remission
02–06	T4NxM1	IV	deceased	-	-	-	-
02–08	T4N1M0	IIIB	remission	remission	remission	disease progression, lung, pleura and liver metastases	no data
02–09	T1N1M0/1	IV	disease progression, bone metastases observed during the 1^st CT round	alive	alive	deceased	-
02–10	T1N1M0	IIA	remission	remission	remission	remission	remission
02–11^a	T2N1M0	IIB	remission	remission	remission	remission	remission
02–14	T2N2M0dex T4N1M0sin	IIIB	remission	remission	remission	remission	remission
02–15	T3N2M0	IIIA	remission	remission	remission	remission	remission
02–16^a	T4NxM0	IIIB	remission	disease progression, metastases in the skin region adjacent to surgery scar	partial regression	deceased	-
02–18^a	T4NxM0	IIIB	remission	remission	remission	remission	remission
AC chemotherapy + Panagen
02–20	T2N1M0	IIB	remission	remission	remission	disease progression, bone metastases	no data
02–21	T2N0M0	IIA	remission	remission	remission	remission	no data
02–22^a	T2N1M0	IIB	remission	remission	remission	remission	no data
02–24	T2N1M0	IIB	remission	remission	remission	remission	no data
02–25^a	T2N2M0	IIIA	remission	remission	remission	remission	no data
02–26	T1N1M0	IIA	remission	remission	remission	remission	no data
02–27	T1N2M0	IIIA	remission	remission	disease progression, bone metastases	no data	no data
02–28^a	T2N1M0	IIB	remission	remission	disease progression, bone and lung metastases	no data	no data
02–29	T2N0M0	IIA	remission	remission	no data	deceased	-
02–30	T2NxM0	II	remission	remission	remission	remission	no data
02–31	T2N1M0/1	IV	disease progression, lung metastases observed 1 month following completion of the therapy	no data	no data	no data	no data
02–33^a	T2N3M0	IIIC	remission	remission	remission	remission	no data
02–36	T4NxM0dex T2NxM0sin	IIIB	treatment continues	treatment continues	no data	no data	no data
02–39	T2N3M0	IIIC	remission	remission	relapse	no data	no data
02–40^a	T2N1M0	IIB	remission	no data	no data	no data	no data
02–42^a	T1N3M0	IIIC	remission	remission	remission	remission	no data
02–43	T3N0M0	IIB	remission	remission	remission	remission	no data
02–44^a	T1N1M0/1	IV	disease progression, bone metastases observed after the 2^ndCT round	no data	no data	no data	no data
02–45^a	T4N1M0	IIIB	remission	remission	disease progression, pleural metastases	no data	no data

Note: ^a – tamoxifen treatment. CT chemotherapy. Patients who progressed or died are shown in boldface. Cause of death in all cases is breast cancer, except patient 01–16. Patient 01–16, whose cause of death was not cancer, didn’t taken into account further

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us